#China #Beijing #Tsingke Biotech #Antibody Solutions #Protein Development

Accelerating Innovation in Biopharma

At the recent PEGS Europe 2025 event, Tsingke Biotech, a prominent biotechnological firm based in Beijing, unveiled cutting-edge advancements in the realm of protein and antibody development. Holding a strategic position among global industry innovators, Tsingke Biotech's exhibit emphasized a major leap forward: the ability to produce proteins in just three days and antibodies in as little as seven. This remarkable speed could redefine drug discovery timelines for biopharmaceutical companies around the globe.

Breaking Down the Technology

Tsingke Biotech has developed a sophisticated system by integrating gene synthesis, automated protein expression, and purification technologies. This comprehensive approach supports a variety of six expression systems including E. coli, Bacillus subtilis, yeast, insect, mammalian, and innovative cell-free systems. For simple proteins, the cell-free method allows for production within 72 hours, while more complex proteins, such as antibodies, can be brought to fruition within a timeframe of 7 to 14 days. The company's success rate for protein expression stands impressively at 95%, marking a significant enhancement over traditional methods.

In focusing on antibody development, Tsingke has transformed the conventional hybridoma approach, which typically requires 1 to 2 months, into an expedited process. Their Single-B Cell Antibody Discovery Service employs natural VH/VL pairing techniques and high-capacity FACS technology to yield antibodies with high affinity within an accelerated 8 to 10-week cycle. This innovative service aims to meet the urgent needs of the R&D sector by ensuring that researchers have access to a diverse range of formats for therapeutic antibodies, collected from both mouse and rabbit models.

Expediting Antibody Production

For actual antibody production, Tsingke Biotech utilizes Expi293 and CHO-K1 systems, yielding milligram amounts in merely 7 days and gram amounts within two weeks. The average production rate exceeds 300 mg/L, catering to various formats including VHH-His and VHH-Fc. Tsingke's comprehensive offerings promise remarkable customization, a feature that has garnered attention among stakeholders within the biopharma industry, ensuring that both simple and complex developmental projects have tailored support.

A Spotlight at PEGS Summit

During PEGS Europe 2025, Tsingke Biotech's booth attracted considerable attention from professionals within the global biopharma community. Engaging discussions indicated a thriving interest in their rapid development solutions, reflecting a wider industry need for enhanced speed, efficiency, and adaptability in protein and antibody production. With leaders from various biopharma companies expressing a desire for collaboration, Tsingke's rapid service offerings could become a defining factor in future partnerships within the sector.

According to Nan Zhang, Global Marketing Manager at Tsingke Biotech, “PEGS is a pivotal event for protein and antibody engineering. Our blend of speed, precision, and customizable solutions is crafted to satisfy the industry's rising demands for expedited drug development.”

Quality and Compliance Standards

Tsingke Biotech’s operations are conducted under ISO 13485 certification, utilizing advanced facilities equipped with Class 100,000 cleanroom environments. This ensures that their high-quality sustainability measures correlate with a smooth transition from research-grade products to workflows compliant with GLP/GMP standards, reinforcing the reliability of their offerings.

Conclusion

In summary, Tsingke Biotech is at the forefront of biotechnological advancements aimed at accelerating the drug discovery process. Their innovative methods not only streamline production but are backed by a commitment to quality and compliance, positioning them as a leader in the field of protein and antibody development. With ongoing innovations and collaborations on the horizon, Tsingke Biotech is set to empower researchers worldwide with their pioneering biomanufacturing capabilities.